Literature DB >> 31236596

GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.

Fumitaka Shimizu1, Yukio Takeshita1, Yasuteru Sano1, Yuka Hamamoto1, Hirokazu Shiraishi2, Takuya Sato1, Shunsuke Yoshimura2, Toshihiko Maeda1, Susumu Fujikawa1, Hideaki Nishihara1, Hiroko Kitanosono2, Akira Tsujino2, Masakatsu Motomura2,3, Takashi Kanda1.   

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of the neuromuscular junction caused by autoantibodies binding to P/Q-type voltage-gated calcium channels. Breakdown of the blood-brain barrier and diffusion of cerebellar granule/Purkinje cell-reactive autoantibodies into the CNS are critical for the pathogenesis of paraneoplastic cerebellar degeneration (PCD) with Lambert-Eaton myasthenic syndrome. We recently found evidence that glucose-regulated protein 78 (GRP78) autoantibodies in the plasma of patients with neuromyelitis optica promote the CNS access of AQP4 autoantibodies. In the present study, we investigated whether the GRP78 autoantibodies in PCD-LEMS IgG boost the brain uptake of cerebellar cell-reactive antibodies across the blood-brain barrier and facilitate cerebellar dysfunction. We first evaluated the effects of purified IgG from PCD-LEMS or PCD patients on the blood-brain barrier function in human brain microvascular endothelial cells using a high content imaging system with nuclear factor κB p65 and intracellular adhesion molecule 1 (ICAM1) immunostaining. Next, we identified GRP78 autoantibodies causing blood-brain barrier permeability in PCD-LEMS IgG by co-immunoprecipitation and the living cell-based antibody binding assays. Exposure of brain microvascular endothelial cells to IgG from PCD-LEMS patients induced nuclear factor κB p65 nuclear translocation, ICAM1 upregulation, reduced claudin-5 expression, increased permeability and increased autocrine IL-1β and IL-8 secretion; the IgG from patients with Lambert-Eaton myasthenic syndrome did not have these effects. We detected GRP78 autoantibodies in the IgG of LEMS-PCD (83.3%, n = 18), but observed fewer in patients with LEMS (6.6%, n = 15) and none were observed in the control subjects (n = 8). The depletion of GRP78 autoantibodies reduced the biological effect of LEMS-PCD IgG on brain microvascular endothelial cells. These findings suggest that GRP78 autoantibodies play a role beyond neuromyelitis optica and that they have direct implications in the phenotypic differences between PCD-LEMS and LEMS.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Lambert-Eaton myasthenic syndrome; blood–brain barrier; glucose-regulated protein 78 autoantibodies; paraneoplastic cerebellar degeneration-Lambert-Eaton myasthenic syndrome

Mesh:

Substances:

Year:  2019        PMID: 31236596     DOI: 10.1093/brain/awz168

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  4 in total

1.  CSF Brain-Reactive Autoantibodies are Elevated in Patients with Viral Encephalitis.

Authors:  Zhong-Yuan Yu; Jian-Hong Wang; Wei-Wei Li; Ye-Ran Wang; Noralyn B Mañucat-Tan; Jun Wang; Ju Wang; Gao-Yu Cui; Jie-Xiang Pan; Shui-Xian Zhang; Zu-Juan Liu; Liang Tan; Yu-Hui Liu
Journal:  Neurosci Bull       Date:  2020-04-30       Impact factor: 5.203

2.  An In Vitro Model of the Blood-Brain Barrier to Study Alzheimer's Disease: The Role of β-Amyloid and Its Influence on PBMC Infiltration.

Authors:  Simona Federica Spampinato; Yukio Takeshita; Birgit Obermeier
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Autoantibodies in neurological disease.

Authors:  Harald Prüss
Journal:  Nat Rev Immunol       Date:  2021-05-11       Impact factor: 53.106

Review 4.  Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases.

Authors:  Mario Gonzalez-Gronow; Salvatore Vincent Pizzo
Journal:  Biomedicines       Date:  2022-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.